BDBM504505 First-eluting enantiomer (see footnote 8 in Table 1); N-[(3S)-5,5-difluoropiperidin-3-yl]-2- {5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3- yl}pyrimidine-5-carboxamide or N-[(3R)-5,5-difluoropiperidin-3-yl]-2- {5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3- yl}pyrimidine-5-carboxamide::US11065249, Example 18::US11065249, Example 19::US11471458, Example 19::US20230405002, Example 18

SMILES CCOc1cccnc1Oc1cncc(c1)-c1ncc(cn1)C(=O)N[C@@H]1CNCC(F)(F)C1

InChI Key InChIKey=STEOFTXCZZHZJZ-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 504505   

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 140nMAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white polypropylene plates (Nunc) in a total volume of 20 μL. To 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 240nMAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white polypropylene plates (Nunc) in a total volume of 20 μL. To 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 140nMAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white polypropylene plates (Nunc) in a total volume of 20 μL. To 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2022
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 240nMAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white polypropylene plates (Nunc) in a total volume of 20 μL. To 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2022
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 20nMAssay Description:Inhibition of DGAT2 in human hepatocytes using [14C]-glycerol as substrate preincubated for 15 mins followed by substrate addition and measured after...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2022
Entry Details Article
PubMed
TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 140nMAssay Description:For determination of IC50 values, the reactions were carried out in 384-well white polypropylene plates (Nunc) in a total volume of 20 μL. To 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2024
Entry Details
Go to US Patent

TargetDiacylglycerol O-acyltransferase 2(Human)
Pfizer

US Patent
LigandPNGBDBM504505(US11065249, Example 19 | First-eluting enantiomer ...)
Affinity DataIC50: 140nMAssay Description:Inhibition of human DGAT2 using 14C decanoyl-CoA as a substrate pre incubated for 2 hrs followed by substrate addition measured after 40 mins by Tril...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2024
Entry Details
PubMed